Wall Street analysts expect that Antares Pharma Inc (NASDAQ:ATRS) will report earnings of ($0.02) per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Antares Pharma’s earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.04). Antares Pharma posted earnings of ($0.01) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 100%. The firm is expected to announce its next earnings report on Tuesday, November 5th.
On average, analysts expect that Antares Pharma will report full-year earnings of ($0.08) per share for the current year, with EPS estimates ranging from ($0.10) to ($0.05). For the next financial year, analysts forecast that the firm will post earnings of $0.16 per share, with EPS estimates ranging from $0.00 to $0.28. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.03. The business had revenue of $28.43 million for the quarter, compared to analyst estimates of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%.
Shares of NASDAQ:ATRS traded up $0.03 during trading on Thursday, hitting $3.31. 22,044 shares of the stock were exchanged, compared to its average volume of 839,594. The company has a fifty day moving average price of $3.19 and a two-hundred day moving average price of $3.10. The company has a market cap of $539.73 million, a PE ratio of -83.00 and a beta of 0.95. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 1.01. Antares Pharma has a 12-month low of $2.53 and a 12-month high of $3.96.
A number of hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its stake in Antares Pharma by 27.9% in the 4th quarter. Bank of New York Mellon Corp now owns 636,911 shares of the specialty pharmaceutical company’s stock worth $1,733,000 after acquiring an additional 138,756 shares during the last quarter. Raymond James & Associates bought a new position in shares of Antares Pharma during the 4th quarter valued at approximately $102,000. Northern Trust Corp increased its position in shares of Antares Pharma by 0.4% during the 4th quarter. Northern Trust Corp now owns 1,741,602 shares of the specialty pharmaceutical company’s stock valued at $4,738,000 after purchasing an additional 6,868 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Antares Pharma by 11.6% during the 4th quarter. Geode Capital Management LLC now owns 1,609,722 shares of the specialty pharmaceutical company’s stock valued at $4,378,000 after purchasing an additional 167,695 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Antares Pharma by 112.6% during the 4th quarter. Bank of America Corp DE now owns 101,544 shares of the specialty pharmaceutical company’s stock valued at $276,000 after purchasing an additional 53,772 shares during the last quarter. 42.65% of the stock is currently owned by hedge funds and other institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Story: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.